Cheng-Cao Sun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2660011/publications.pdf

Version: 2024-02-01

46

all docs

41 3,247 33
papers citations h-index

46

docs citations

h-index g-index

46
4189
times ranked citing authors

265206

42

| # | Article | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway., 2022, 10, e004113. | | 16 |
| 2 | Mechanism of efficient double-strand break repair by a long non-coding RNA. Nucleic Acids Research, 2020, 48, 10953-10972. | 14.5 | 43 |
| 3 | The IncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nature Cell Biology, 2020, 22, 1332-1345. | 10.3 | 51 |
| 4 | FOXC1-mediated LINC00301 facilitates tumor progression andÂtriggers anÂimmune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway. Genome Medicine, 2020, 12, 77. | 8.2 | 107 |
| 5 | Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology. Molecular Cancer, 2020, 19, 102. | 19.2 | 129 |
| 6 | LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Molecular Cancer, 2019, 18, 141. | 19.2 | 80 |
| 7 | Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia. Molecular Therapy - Oncolytics, 2019, 12, 103-111. | 4.4 | 40 |
| 8 | Emerging landscape of circular RNAs in lung cancer. Cancer Letters, 2018, 427, 18-27. | 7.2 | 93 |
| 9 | Long intergenic non-protein coding RNA 319 aggravates lung adenocarcinoma carcinogenesis by modulating miR-450b-5p/EZH2. Gene, 2018, 650, 60-67. | 2.2 | 59 |
| 10 | Long non coding RNA XIST as a prognostic cancer marker – A meta-analysis. Clinica Chimica Acta, 2018, 482, 1-7. | 1.1 | 31 |
| 11 | Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging, 2018, 10, 973-987. | 3.1 | 70 |
| 12 | MiRNA-based Therapeutic Strategy in Lung Cancer. Current Pharmaceutical Design, 2018, 23, 6011-6018. | 1.9 | 28 |
| 13 | Editorial: Towards MiRNA Based Therapeutics for Lung Cancer. Current Pharmaceutical Design, 2018, 23, 5971-5972. | 1.9 | 5 |
| 14 | miR-134: A Human Cancer Suppressor?. Molecular Therapy - Nucleic Acids, 2017, 6, 140-149. | 5.1 | 96 |
| 15 | CDK3 is a major target of miR-150 in cell proliferation and anti-cancer effect. Experimental and Molecular Pathology, 2017, 102, 181-190. | 2.1 | 8 |
| 16 | The IncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2. Molecular Therapy - Nucleic Acids, 2017, 9, 100-110. | 5.1 | 105 |
| 17 | Micro <scp>RNA</scp> s: A novel potential biomarker for diagnosis and therapy in patients with nonâ€small cell lung cancer. Cell Proliferation, 2017, 50, . | 5.3 | 98 |
| 18 | miR-206/133b Cluster: A Weapon against Lung Cancer?. Molecular Therapy - Nucleic Acids, 2017, 8, 442-449. | 5.1 | 40 |

| # | Article | IF | Citations |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Echinocystic acid ameliorates hyperhomocysteinemiaâ€ʻinduced vascular endothelial cell injury through regulating NFâ€ÎºB and CYP1A1. Experimental and Therapeutic Medicine, 2017, 14, 4174-4180. | 1.8 | 4 |
| 20 | Sirtuin 1 promotes the proliferation of C2C12 myoblast cells via the myostatin signaling pathway. Molecular Medicine Reports, 2016, 14, 1309-1315. | 2.4 | 15 |
| 21 | MicroRNA-346 facilitates cell growth and metastasis, and suppresses cell apoptosis in human non-small cell lung cancer by regulation of XPC/ERK/Snail/E-cadherin pathway. Aging, 2016, 8, 2509-2524. | 3.1 | 92 |
| 22 | 585. Long Non-Coding RNA NEAT1 Functions as a ceRNA to Regulate E2F3 Expression by Sponging miR-377-3p in Non-Small Cell Lung Cancer. Molecular Therapy, 2016, 24, S232. | 8.2 | 0 |
| 23 | The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer. Medical Oncology, 2016, 33, 124. | 2.5 | 22 |
| 24 | Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression. Biochemical and Biophysical Research Communications, 2016, 478, 811-817. | 2.1 | 180 |
| 25 | Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non–small-cell Lung Cancer by Binding to EZH2 and Suppressing p57. Molecular Therapy - Nucleic Acids, 2016, 5, e385. | 5.1 | 192 |
| 26 | The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non–small-cell Lung Cancer Through Altering STAT3 Expression. Molecular Therapy - Nucleic Acids, 2016, 5, e387. | 5.1 | 78 |
| 27 | MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6. Biochemical and Biophysical Research Communications, 2016, 471, 82-88. | 2.1 | 107 |
| 28 | Red Meat Consumption and the Risk of Stroke: A Dose–Response Meta-analysis of Prospective Cohort Studies. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1177-1186. | 1.6 | 79 |
| 29 | Sulforaphane mitigates muscle fibrosis in <i>mdx</i> mice via Nrf2-mediated inhibition of TGF-l²/Smad signaling. Journal of Applied Physiology, 2016, 120, 377-390. | 2.5 | 71 |
| 30 | Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer. Cancer Gene Therapy, 2016, 23, 90-97. | 4.6 | 43 |
| 31 | Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. Oncotarget, 2016, 7, 51784-51814. | 1.8 | 270 |
| 32 | Hsa-miR-326 targets <i>CCND1</i> and inhibits non-small cell lung cancer development. Oncotarget, 2016, 7, 8341-8359. | 1.8 | 110 |
| 33 | Hsa-miR-329 exerts tumor suppressor function through down-regulation of <i>MET</i> in non-small cell lung cancer. Oncotarget, 2016, 7, 21510-21526. | 1.8 | 66 |
| 34 | Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget, 2016, 7, 35960-35978. | 1.8 | 90 |
| 35 | Down-regulation of <i>c-Met</i> and <i>Bcl2</i> by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget, 2015, 6, 25533-25574. | 1.8 | 114 |
| 36 | microRNA miR-10b inhibition reduces cell proliferation and promotes apoptosis in non-small cell lung cancer (NSCLC) cells. Molecular BioSystems, 2015, 11, 2051-2059. | 2.9 | 55 |

| # | Article | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient mdx Mice via NF-E2-related Factor 2 (Nrf2)-mediated Inhibition of NF-κB Signaling Pathway. Journal of Biological Chemistry, 2015, 290, 17784-17795. | 3.4 | 143 |
| 38 | Sulforaphane alleviates muscular dystrophy in <i>mdx</i> mice by activation of Nrf2. Journal of Applied Physiology, 2015, 118, 224-237. | 2.5 | 67 |
| 39 | miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis. Journal of Gastroenterology, 2015, 50, 480-490. | 5.1 | 37 |
| 40 | Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget, 2015, 6, 39756-39792. | 1.8 | 107 |
| 41 | Targeting TFAP2C/PDCD6 Pathway by IncRNA PP7080 Expedites Tumorigenesis and Contributes to an Immunosuppressive Tumor Microenvironment in Nonâ€Small Cell Lung Cancer. Advanced Therapeutics, 0, , 2100184. | 3.2 | 1 |